Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Alto Neuroscience (ANRO) Shares Outstanding (Weighted Average) (2023 - 2026)

Alto Neuroscience has reported Shares Outstanding (Weighted Average) over the past 4 years, most recently at $32.9 million for Q1 2026.

  • Quarterly results put Shares Outstanding (Weighted Average) at $32.9 million for Q1 2026, up 21.61% from a year ago — trailing twelve months through Mar 2026 was $32.9 million (up 21.61% YoY), and the annual figure for FY2025 was $28.9 million, up 17.28%.
  • Shares Outstanding (Weighted Average) reached $32.9 million in Q1 2026 per ANRO's latest filing, up from $28.9 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $32.9 million in Q1 2026 and bottomed at $3.7 million in Q1 2023.
  • Median Shares Outstanding (Weighted Average) over the past 4 years was $24.6 million (2024), compared with a mean of $19.2 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) skyrocketed 625.29% in 2024 before it increased 0.54% in 2025.
  • Over 4 years, Shares Outstanding (Weighted Average) stood at $3.7 million in 2023, then soared by 559.39% to $24.6 million in 2024, then rose by 17.28% to $28.9 million in 2025, then rose by 14.01% to $32.9 million in 2026.
  • Business Quant data shows Shares Outstanding (Weighted Average) for ANRO at $32.9 million in Q1 2026, $28.9 million in Q4 2025, and $27.1 million in Q3 2025.